Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home
NCT ID: NCT01676688
Last Updated: 2023-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
17 participants
OBSERVATIONAL
2012-01-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis
NCT02010411
The Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
NCT00405665
Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients
NCT02598999
Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients
NCT00506688
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
NCT00157092
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients above 18 y.o,
* suffering from severe forms of primary alpha-1 antitrypsin deficiency, phenotype PiZZ or PiSZ with pulmonary emphysema,
* currently treated as per routine practice, once a week, by ALFALASTIN® at home or in out-of-hospital location
* and having signed informed consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoire français de Fractionnement et de Biotechnologies
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cuvelier Antoine, Prof.
Role: STUDY_DIRECTOR
Pneumology - CHU Rouen, France
Mornex Jean-François, Prof
Role: STUDY_CHAIR
Pneumology - CHU Lyon, France
Thabut Gabriel, MD
Role: STUDY_CHAIR
Pneumology - Hôpital Bichat Paris, France
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AlfaDom
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.